A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma Patients.

Authors :: Mateos, M.V.
Blade, Joan
Mediavilla, J. Diaz
Lahuerta, J.J.
Terol, M.J.
Hernández, J.
Moro, M.J.
Bargay, J.
Ribera, J.M.
de la Rubia, J.
Sureda, A.
Carrera, D.
de Arriba, F.
Palomera, L.
Hernández, M.
Laraña, J. García
Alegre, A.
Prosper, F.
Rivas, P.
Esseltine, D.L.
Schenkein, D.
Miguel, J.F. San
Source :: Blood; November 2004, Vol. 104 Issue: 11 p3462-3462, 1p
Publication Year :: 2004
Abstract: For more than 25 years, melphalan and prednisone has remained as the gold standard treatment for elderly multiple myeloma (MM) patients. Bortezomib has shown significant activity with manageable toxicity in refractory/relapse MM patients. Moreover, in vitro synergy has been reported when bortezomib is combined with cytotoxic agents such as melphalan.

Full Text Access

Tools